StockpollyBeta
Get App
Popularity #98
CAPR · NASDAQ · Biotechnology

Capricor Therapeutics (CAPR)

Develops deramiocel for Duchenne muscular dystrophy and StealthX exosome therapies.

$8.57
vs last close−0.77 (−8.27%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue61254211000000
Cost of revenue01011131215192220000
Gross profit62−6−9−10−3−19−22−20000
1334334666293743
Research & development101011131215192220232729
3343346666914
General & administrative3343346660914
Other expenses0−10−11−13−12−15−19−22−20000
Operating income−7−1−10−12−13−8−25−28−26−29−37−43
010101122−132
Interest income000101122232
Interest expense000000000300
Other non-operating income0−10−10−1−1−2−2−2−3−2
Income before tax−6−1−10−11−13−7−24−26−25−30−34−41
Income tax expense000000000000
Net income from continuing operations−6−1−10−11−13−7−24−26−25−30−34−41
Net income−6−1−10−11−13−7−24−26−25−30−34−41
EPS, basic−$0.25−$0.02−$0.31−$0.35−$0.38−$0.16−$0.53−$0.57−$0.54−$0.62−$0.59−$0.70
EPS, diluted−$0.25−$0.02−$0.31−$0.35−$0.38−$0.16−$0.53−$0.57−$0.54−$0.62−$0.59−$0.70
Weighted average shares, basic262731323335464646495758
Weighted average shares, diluted262731323335464646495758
EBITDA−70−9−11−12−7−24−25−24976−33255
Depreciation & amortization0000000001,0031296
EBIT−7−1−10−11−13−7−24−26−25−27−34−41